Cytolytic characteristics of HATGF-βRII-Δcyt–transduced versus nontransduced cytotoxic T-lymphocyte lines with and without exposure to exogenous transforming growth factor β
| CTL line . | % Specific lysis (ratio 10:1) . | Day of culture* (d after transduction) . | |||
|---|---|---|---|---|---|
| Nontransduced . | TGF-βRII-Δcyt transduced . | ||||
| Auto LCL . | Auto LCL + TGF-β . | Auto LCL . | Auto LCL + TGF-β . | ||
| Patient 1 | 69 | 27 | 63 | 66 | 70 (21) |
| Patient 2 | 43 | 18 | 40 | 41 | 96 (14) |
| Patient 3 | 41 | 24 | 30 | 35 | 88 (26) |
| Patient 4 | 26 | 3 | 27 | 23 | 120 (21) |
| Donor 1 | 37 | 19 | 44 | 54 | 42 (26) |
| Donor 2 | 95 | 69 | 44 | 53 | 56 (21) |
| Donor 3 | 64 | 54 | 48 | 42 | 52 (14) |
| Donor 4 | 61 | 36 | 22 | 23 | 52 (14) |
| CTL line . | % Specific lysis (ratio 10:1) . | Day of culture* (d after transduction) . | |||
|---|---|---|---|---|---|
| Nontransduced . | TGF-βRII-Δcyt transduced . | ||||
| Auto LCL . | Auto LCL + TGF-β . | Auto LCL . | Auto LCL + TGF-β . | ||
| Patient 1 | 69 | 27 | 63 | 66 | 70 (21) |
| Patient 2 | 43 | 18 | 40 | 41 | 96 (14) |
| Patient 3 | 41 | 24 | 30 | 35 | 88 (26) |
| Patient 4 | 26 | 3 | 27 | 23 | 120 (21) |
| Donor 1 | 37 | 19 | 44 | 54 | 42 (26) |
| Donor 2 | 95 | 69 | 44 | 53 | 56 (21) |
| Donor 3 | 64 | 54 | 48 | 42 | 52 (14) |
| Donor 4 | 61 | 36 | 22 | 23 | 52 (14) |
Percentage of specific 51Cr release was determined after 4-hour coincubation with autologous lymphoblastoid cell line (LCL) in cytotoxic T-lymphocyte (CTL) lines with and without transforming growth factor β (TGF-β) added to CTL cultures 96 hours before the cytotoxicity assay. The table shows the percentage of specific lysis at an effector-to-target ratio of 10:1 in the CTL lines generated from 4 healthy donors and 4 patients with Hodgkin disease. The far right column shows the day of CTL culture/and day after transduction when the cytotoxicity assay was performed.
Cytotoxicity of transduced and nontransduced CTLs was tested on the same day of culture.